Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig versus standard available therapy in relapsed or refractory multiple myeloma after 2 or more prior lines
2023-506668-15-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of etentamig in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-free survival and Overall response rate. Planned start Jun 2024; status: authorised.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-506668-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506668-15-00.